Moreover, 34% of GLY low /TME high patients responded to immunotherapy, compared to 25% and 29% in the GLY high /TME low and mixed groups, respectively, with a decreasing trend ( Figure 7 B).
← all excerpts
Integrating TCGA and Single-Cell Sequencing Data for Hepatocellular Carcinoma: A Novel Glycosylation (GLY)/Tumor Microenvironment (TME) Classifier to Predict Prognosis and Immunotherapy Response.
1
—
—